Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

The Company previously announced that the Phase 2 results with AT2220 will be available in the second half of 2009. The Company will provide updated guidance for reporting results in the upcoming months.

These events have no impact on Amicus' ongoing studies with its investigational drugs Amigal(TM) (migalastat hydrochloride) for Fabry disease and Plicera(TM) (afegostat tartrate) for Gaucher disease.

About the Phase 2 Trial with AT2220

Amicus initiated a multi-national, open-label Phase 2 clinical trial designed to enroll 18 adult patients diagnosed with Pompe disease. The primary objective of the study is to evaluate the safety and tolerability of different dosing regimens of AT2220 over a 12-week period. The study will also explore certain pharmacodynamic and pharmacokinetic measures including the effect of treatment with AT2220 on GAA activity and on glycogen levels in various cells and tissues. Additional objectives include preliminary assessments of pulmonary and skeletal muscle function. Participants who complete the study may be eligible to participate in a voluntary extension study that will further evaluate the effect of AT2220 on these functional parameters.

Additional information about the Phase 2 study is posted at www.clinicaltrials.gov.

The initiation of the Phase 2 study of AT2220 followed completion of multiple Phase 1 studies of AT2220 in healthy volunteers. Data from the Phase 1 studies in 72 healthy volunteers demonstrated that AT2220 was generally safe and well tolerated at all doses evaluated with no drug-related serious adverse events.

Amicus is developing AT2220 as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosoma
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Market by Equipment Type (Benchtop, Mobile, Industrial, & ... Others), Technology (Tray-style, Manifold, & Rotary) & Geography ... by MarketsandMarkets, defines and segments the lyophilization market ... regions with analyses and projections of the market ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , , FARMINGDALE, N.Y., Jan. 11 Misonix, ... invasive ultrasonic medical device technology, which in Europe is ... other acute health conditions, has entered into a new, ... in Lima, Peru, for the distribution of the SonaStar(TM) ...
... , BETHESDA, Md., Jan. 11 Spherix Inc. (Nasdaq: ... a provider of technical and regulatory consulting services to food, ... Dr. Robert Lodder, will be presenting at the Annual OneMedPlace ... Drake Hotel in San Francisco, CA. Dr. Lodder will ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Peru 2Misonix Announces New Distribution Agreement for Peru 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up ... credit card information pilfered by hackers, surpassing the 40 million ... articles like this one published by Bloomberg on ... , “Most people tend to focus on how many ... to score a game,” says Joe Caruso, founder and CEO/CTO ...
(Date:9/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers. , “Fun, cool, and simple are ... says Christina Austin, CEO of Pixel Film Studios. “It has ... features easy to use controls that give the user the ... background color, color of each circle outline, the position of ...
(Date:9/20/2014)... Everett, WA (PRWEB) September 20, 2014 “Motherhood ... Health Center of Snohomish in their latest article , ... the best that you can—and that’s what we want to ... what services they need and should expect from their Family ... the following days of new motherhood. , To learn ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving ... a meeting took place to discuss the next steps ... the court’s mass tort program. Attorneys for the plaintiffs ... at the Complex Litigation Center in Philadelphia’s City Hall ... The Risperdal lawsuits filed against Johnson & Johnson and ...
(Date:9/19/2014)... September 19, 2014 Are you tired ... of problems with seasonal allergies or sinus congestion? Fortunately, ... better alternative. , She conceived of Nose Pal ... a runny nose in public. Since it prevents nasal ... more sanitary conditions, particularly when cooking or working closely ...
Breaking Medicine News(10 mins):Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... determine how arsenic increases the risk of lung cancer ... researcher will use $1.7 million in federal funding during ... disrupt cells, leading to the disease. Chengfeng Yang, ... Medicine and MSU,s Center for Integrative Toxicology, will be ...
... National Medical Center, in partnership with The George ... and Translational Science Award (CTSA) from the National Center ... This award, which totals $20 million over ... a children,s hospital. The Clinical and Translational Science ...
... morbidly obese diabetics is causing more new cases of a ... make walking difficult or impossible, and in severe cases can ... bones with an external frame has enabled more than 90 ... University Health System foot and ankle surgeon Dr. Michael Pinzur. ...
... New and updated guidelines on recommended vitamin D intake have ... Canadian Medical Association Journal ( CMAJ ). ... of Medicine, and member of Osteoporosis Canada,s (OC) Scientific Advisory ... of Osteoporosis Canada. "OC,s current recommendations on vitamin D ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, July 13 ... will last ",til death do you part" -- or if ... association game may reveal the hidden truth about your union, ... is flawed because it relies on asking the people involved ...
... common ― and often ineffective ― ways of fighting ... new study from Tel Aviv University shows why they,re ... psychologically-based smoking cessation programs. In the new study ... Dr. Reuven Dar of Tel Aviv University,s Department of ...
Cached Medicine News:Health News:Researcher targets gene regulators on link between arsenic, cancer 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 3Health News:New treatment for crippling diabetic Charcot foot 2Health News:New vitamin D guidelines 2Health News:Word Games May Predict Life of Relationship 2Health News:Word Games May Predict Life of Relationship 3Health News:Smoking mind over smoking matter 2Health News:Smoking mind over smoking matter 3
2 mm wide x 3 mm long, tapered handle. Angled 45 degrees. Round handle....
1.5 mm long blade. Square handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Medicine Products: